Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.51 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.48 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19880370 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2FKBP1AMMEL1SLC6A1NPC1 | |
| SCHEMBL19880369 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2FKBP1AMMEL1SLC6A1NPC1 | |
| SCHEMBL14836855 | 0.96 | MMEL1 (0.52) | SMN1; SMN2FKBP1AMMEL1NPC1RAB9A | |
| SCHEMBL3912914 | 0.87 | POLB (0.62) | SMN1; SMN2FKBP1AMMEL1POLBALDH1A1 | |
| SCHEMBL24705627 | 0.86 | SPHK1 (0.50) | SMN1; SMN2FKBP1AMMEL1NPC1RAB9A | |
| SCHEMBL18626013 | 0.86 | SPHK1 (0.50) | SMN1; SMN2FKBP1AMMEL1NPC1RAB9A | |
| SCHEMBL20966402 | 0.86 | SPHK1 (0.58) | SMN1; SMN2FKBP1AMMEL1POLBALDH1A1 | |
| SCHEMBL934366 | 0.84 | MMEL1 (0.58) | FKBP1AMMEL1ACEPOLBALDH1A1 | |
| SCHEMBL20966406 | 0.84 | MMEL1 (0.53) | SMN1; SMN2FKBP1AMMEL1ACE | |
| SCHEMBL2707345 | 0.84 | MMEL1 (0.58) | FKBP1AMMEL1ACEPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896452-B2 | Substituted prolines/piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170101410-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | EOLAS THERAPEUTICS, INC. | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101410-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OPRL1 | SMN1; SMN2 856/4885FKBP1A 200/4885MMEL1 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.